抗がん剤MAbSの世界市場レポート 2024年

抗がん剤：モノクローナル抗体（MAbS）の市場規模は近年急速に拡大しています。2023年の599億8,000万米ドルから2024年には661億米ドルへと、CAGR10.2％で拡大します。抗がんモノクローナル抗体の分野で過去一定期間に観察された成長は、いくつかの要因に起因しています。がんの罹患率の増加、がん生物学に対する理解の深まりによる標的治療への道筋の確立、個々の患者に合わせた治療を行う個別化医療の台頭、がん治療の研究開発への投資の増加、高度で効果的ながん治療に対する患者の意識と需要の並行的な高まりなどです。これらの要因は、歴史的な期間に抗がんモノクローナル抗体の開発と採用に総合的に貢献しました。

世界のがん罹患率の増加は、抗がん剤mAbs市場の成長を促進すると予想されます。がんは慢性疾患であり、世界中で数百万人が罹患しています。抗がんモノクローナル抗体は、がん細胞上に存在する特定のタンパク質を標的として設計されており、がん細胞と闘うために免疫系の抗体の遺伝子組み換えバージョンを使用します。がんの有病率の上昇に伴い、抗がんmAbsのようなより効果的な治療法に対する需要が高まっています。例えば、PubMedの2022年1月の報告によると、世界全体で190万人のがん患者が新たに発生し、米国では60万9360人のがん関連死が予想されています。その結果、がんの有病率の増加が抗がん剤mAbs市場の成長の重要な促進要因となっています。

2023年の抗がん剤MAbS市場では北米が最大地域でした。アジア太平洋地域は、予測期間中に抗がん剤MAbS市場で最も急成長する地域となる見込みです。抗がん剤MAbS市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 抗がん剤MAbS市場の特徴

第3章 抗がん剤MAbS市場の動向と戦略

第4章 抗がん剤MAbS市場- マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の抗がん剤MAbS市場の規模と成長

• 世界の抗がん剤MAbS市場促進要因と制約要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の抗がん剤MAbS市場規模の実績と成長、2018-2023
• 世界の抗がん剤MAbS市場規模と成長予測、2023-2028、2033年

第6章 抗がん剤MAbS市場セグメンテーション

• 世界の抗がん剤MAbS市場、タイプ別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • ネズミ抗体
  • キメラ抗体
  • ヒト化抗体
  • その他のタイプ
• 世界の抗がん剤MAbS市場、用途別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • 血液がん
  • 乳がん
  • 肺がん
  • 黒色腫
  • 結腸直腸がん
  • 肝臓がん
  • その他の用途
• 世界の抗がん剤MAbS市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028、2033年
  • 病院
  • 調査機関
  • その他のエンドユーザー

第7章 抗がん剤MAbS市場の地域および国分析

• 世界の抗がん剤MAbS市場、地域別、実績および予測、2018-2023、2023-2028、2033年
• 世界の抗がん剤MAbS市場、国別、実績および予測、2018-2023、2023-2028、2033年

第8章 アジア太平洋の抗がん剤MAbS市場

第9章 中国の抗がん剤MAbS市場

第10章 インドの抗がん剤MAbS市場

第11章 日本の抗がん剤MAbS市場

第12章 オーストラリアの抗がん剤MAbS市場

第13章 インドネシアの抗がん剤MAbS市場

第14章 韓国の抗がん剤MAbS市場

第15章 西欧の抗がん剤MAbS市場

第16章 英国の抗がん剤MAbS市場

第17章 ドイツの抗がん剤MAbS市場

第18章 フランスの抗がん剤MAbS市場

第19章 イタリアの抗がん剤MAbS市場

第20章 スペインの抗がん剤MAbS市場

第21章 東欧の抗がん剤MAbS市場

第22章 ロシアの抗がん剤MAbS市場

第23章 北米の抗がん剤MAbS市場

第24章 米国の抗がん剤MAbS市場

第25章 カナダの抗がん剤MAbS市場

第26章 南米の抗がん剤MAbS市場

第27章 ブラジルの抗がん剤MAbS市場

第28章 中東の抗がん剤MAbS市場

第29章 アフリカの抗がん剤MAbS市場

第30章 抗がん剤MAbS市場の競合情勢と企業プロファイル

• 抗がん剤MAbS市場の競合情勢
• 抗がん剤MAbS市場の企業プロファイル
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

第31章 世界の抗がん剤MAbS市場の競合ベンチマーキング

第32章 世界の抗がん剤MAbS市場競争ダッシュボード

第33章 抗がん剤MAbS市場における主要な合併と買収

第34章 抗がん剤MAbS市場の将来展望と可能性分析

第35章 付録

“Anti-Cancer MAbS Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-cancer mobs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-cancer mobs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anti-cancer mobs market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Type: Murine Antibodies; Chimeric Antibodies; Humanized Antibodies; Other Types
• 2) By Application: Blood Cancer; Breast Cancer; Lung Cancer; Melanoma; Colorectal Cancer; Liver Cancer; Other Applications
• 3) By End User: Hospitals; Research Institutes; Other End Users
• Companies Mentioned: Amgen Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anticancer monoclonal antibodies (mAbs) are antibodies utilized in monoclonal antibody therapy with the aim of targeting and destroying cancer cells. These antibodies are designed to bind to specific proteins or chemicals found on the surface of cancer cells, thereby inhibiting the growth and spread of cancer.

The primary types of anti-cancer mAbs include murine antibodies, chimeric antibodies, humanized antibodies, and others. Murine antibodies are a specific category of monoclonal antibodies that are laboratory-made copies of a single antibody. These antibodies are produced by a single B cell and are derived from mice or rats. They are engineered to bind to a specific antigen. Anticancer mAbs find applications in various cancer types, including blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, among others. These antibodies are used in settings such as hospitals, research institutes, and other medical facilities.

The anti-cancer MABs market research report is one of a series of new reports from The Business Research Company that provides anti-cancer MABs market statistics, including anti-cancer MABs industry global market size, regional shares, competitors with an anti-cancer MABs market share, detailed anti-cancer MABs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-cancer MABs industry. This anti-cancer MABs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed during the historical period in the field of anticancer monoclonal antibodies can be attributed to several factors. These include the increasing incidence rates of cancer, a growing understanding of cancer biology that has paved the way for targeted therapies, the rise in personalized medicine approaches tailoring treatments to individual patients, increased investment in research and development for cancer treatments, and a parallel increase in patient awareness and demand for advanced and effective cancer therapies. These factors collectively contributed to the development and adoption of anticancer monoclonal antibodies during the historic period.

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period in the field of anticancer monoclonal antibodies can be attributed to several factors. These include advancements in immunotherapy, the increasing adoption of combination therapies for more effective cancer treatment, the emergence of next-generation monoclonal antibodies, global efforts to address the burden of cancer, and the expansion of patient access programs to ensure broader availability of these therapies. Key trends expected in the forecast period encompass innovations in drug delivery technologies, the integration of artificial intelligence in drug discovery processes, collaborative initiatives and partnerships within the pharmaceutical industry, advancements in biotechnology, and the ongoing development of CAR-T cell therapies for cancer treatment. These trends collectively contribute to the continued evolution and expansion of the anticancer monoclonal antibody sector.

The increasing incidence of cancer worldwide is expected to drive the growth of the anticancer monoclonal antibodies (mAbs) market. Cancer is a chronic disease that affects millions of individuals globally. Anticancer mAbs are designed to target specific proteins found on cancer cells, using genetically engineered versions of the immune system's antibodies to combat cancerous cells. With the rising prevalence of cancer, there is a growing demand for more effective therapies such as anticancer mAbs. For instance, according to a January 2022 report from PubMed, an estimated 1.9 million new cancer cases are anticipated globally, with 609,360 cancer-related deaths expected in the United States. Consequently, the increasing prevalence of cancer is a significant driver for the growth of the anticancer mAbs market.

The proliferation of clinical trials is anticipated to further fuel the expansion of the anti-cancer mAbs market. Clinical trials play a vital role in advancing and refining anti-cancer monoclonal antibodies by evaluating their safety, efficacy, and potential mechanisms of action. They offer valuable insights into health-related biomedical or behavioral outcomes and are pivotal in the development and enhancement of these therapies. For instance, according to the World Health Organization's February 2023 report, the number of global clinical trials increased by 20%, reaching 744,100 trials in 2022 from 616,765 in 2020. This growth in clinical trials is a key factor driving the expansion of the anti-cancer mAbs market.

Product innovation is a prominent trend within the anticancer mAbs market, with major companies introducing more targeted and effective cancer treatments. For example, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, launched PHESGO, a unique combination treatment for HER2-positive early breast cancer. PHESGO consists of two monoclonal antibodies, pertuzumab and trastuzumab, combined with the enzyme hyaluronidase. This subcutaneous injection, leveraging hyaluronidase, enhances mAbs absorption, allowing for subcutaneous administration rather than intravenous, offering patients a more convenient treatment option. Such innovative approaches demonstrate a commitment to developing advanced and patient-friendly therapies within the anticancer mAbs market.

Major players in the anti-cancer monoclonal antibodies (mAbs) market are strategically focusing on innovative strategies, such as conducting clinical trials, to establish a competitive advantage in the industry. Clinical trials are pivotal research studies that assess the safety and efficacy of novel treatments, medications, or devices in human subjects. For instance, in April 2023, Y-mAbs Therapeutics Inc., a prominent clinical biopharmaceutical company based in the United States, initiated a Phase I Trial for GD2-Targeted Radioimmunotherapy. This trial aims to evaluate the safety and effectiveness of GD2-SADA, a pre-targeted radioimmunotherapy (RIT), in treating specific GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. GD2-SADA follows a distinctive two-step procedure to administer radiation to tumor cells. Initially, the SADA protein attaches to GD2 proteins present on the surface of various solid tumors. Subsequently, the radioactive ligand 177Lu-DOTA is introduced, binding to the SADA protein and delivering radiation specifically to the tumor cells. This two-step approach is devised to limit radiation exposure to healthy tissues.

In May 2021, Exelixis Inc., a US-based company specializing in genomics-based drug discovery, completed the acquisition of GamaMabs Pharma SA for $5 million. This acquisition was undertaken to integrate GamaMabs' AMHR2 antibody technology into Exelixis Inc.'s assets, thereby expanding its current drug product portfolio with GamaMabs' offerings and associated manufacturing cell lines. GamaMabs Pharma SA, based in France, is a biotechnology company dedicated to the development of innovative monoclonal antibodies specifically designed for treating solid tumors.

Major companies operating in the anti-cancer mabs market report are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, Kite Pharma, ADC Therapeutics, MacroGenics Inc., BioXcel Therapeutics, Zymeworks Inc., Exelixis Inc., Blueprint Medicines, Erytech Pharma, Oncopeptides AB .

North America was the largest region in the anti-cancer MAbS market in 2023. Asia Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-cancer mabs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticancer mAbs market consists of sales of monoclonal antibody therapies such as avastin, Herceptin, keytruda, opdivo, darzalex, and perjeta. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Anti-Cancer MAbS Market Characteristics

3. Anti-Cancer MAbS Market Trends And Strategies

4. Anti-Cancer MAbS Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Anti-Cancer MAbS Market Size and Growth

• 5.1. Global Anti-Cancer MAbS Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Anti-Cancer MAbS Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Anti-Cancer MAbS Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anti-Cancer MAbS Market Segmentation

• 6.1. Global Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Murine Antibodies
• Chimeric Antibodies
• Humanized Antibodies
• Other Types
• 6.2. Global Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Other Applications
• 6.3. Global Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Research Institutes
• Other End Users

7. Anti-Cancer MAbS Market Regional And Country Analysis

• 7.1. Global Anti-Cancer MAbS Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Anti-Cancer MAbS Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anti-Cancer MAbS Market

• 8.1. Asia-Pacific Anti-Cancer MAbS Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anti-Cancer MAbS Market

• 9.1. China Anti-Cancer MAbS Market Overview
• 9.2. China Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anti-Cancer MAbS Market

• 10.1. India Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anti-Cancer MAbS Market

• 11.1. Japan Anti-Cancer MAbS Market Overview
• 11.2. Japan Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anti-Cancer MAbS Market

• 12.1. Australia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anti-Cancer MAbS Market

• 13.1. Indonesia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anti-Cancer MAbS Market

• 14.1. South Korea Anti-Cancer MAbS Market Overview
• 14.2. South Korea Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anti-Cancer MAbS Market

• 15.1. Western Europe Anti-Cancer MAbS Market Overview
• 15.2. Western Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anti-Cancer MAbS Market

• 16.1. UK Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anti-Cancer MAbS Market

• 17.1. Germany Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anti-Cancer MAbS Market

• 18.1. France Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anti-Cancer MAbS Market

• 19.1. Italy Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anti-Cancer MAbS Market

• 20.1. Spain Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anti-Cancer MAbS Market

• 21.1. Eastern Europe Anti-Cancer MAbS Market Overview
• 21.2. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anti-Cancer MAbS Market

• 22.1. Russia Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anti-Cancer MAbS Market

• 23.1. North America Anti-Cancer MAbS Market Overview
• 23.2. North America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anti-Cancer MAbS Market

• 24.1. USA Anti-Cancer MAbS Market Overview
• 24.2. USA Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anti-Cancer MAbS Market

• 25.1. Canada Anti-Cancer MAbS Market Overview
• 25.2. Canada Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anti-Cancer MAbS Market

• 26.1. South America Anti-Cancer MAbS Market Overview
• 26.2. South America Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anti-Cancer MAbS Market

• 27.1. Brazil Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anti-Cancer MAbS Market

• 28.1. Middle East Anti-Cancer MAbS Market Overview
• 28.2. Middle East Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anti-Cancer MAbS Market

• 29.1. Africa Anti-Cancer MAbS Market Overview
• 29.2. Africa Anti-Cancer MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Anti-Cancer MAbS Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Anti-Cancer MAbS Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anti-Cancer MAbS Market Competitive Landscape And Company Profiles

• 30.1. Anti-Cancer MAbS Market Competitive Landscape
• 30.2. Anti-Cancer MAbS Market Company Profiles
  • 30.2.1. Amgen Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bristol Myers Squibb Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Eli Lilly and Company
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. F. Hoffmann-La Roche Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. GlaxoSmithKline plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Anti-Cancer MAbS Market Competitive Benchmarking

32. Global Anti-Cancer MAbS Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Anti-Cancer MAbS Market

34. Anti-Cancer MAbS Market Future Outlook and Potential Analysis

• 34.1 Anti-Cancer MAbS Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Anti-Cancer MAbS Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Anti-Cancer MAbS Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer